Back
CorMedix, Inc. 10K Form
Sell
44
CRMD
CorMedix, Inc.
Last Price:
$10.65
Seasonality Move:
51.75%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2023-11-14 | 10Q | CRMD/CorMedix, Inc. Quarterly |
| 2023-08-08 | 10Q | CRMD/CorMedix, Inc. Quarterly |
| 2023-05-15 | 10Q | CRMD/CorMedix, Inc. Quarterly |
| 2022-11-10 | 10Q | CRMD/CorMedix, Inc. Quarterly |
| 2022-08-11 | 10Q | CRMD/CorMedix, Inc. Quarterly |
| 2022-05-12 | 10Q | CRMD/CorMedix, Inc. Quarterly |
Receive CRMD News And Ratings
See the #1 stock for the next 7 days that we like better than CRMD
CRMD Financial Statistics
Sales & Book Value
| Annual Sales: | $43.5M |
|---|---|
| Cash Flow: | $30.4M |
| Price / Cash Flow: | 10.32 |
| Annual Sales: | $4.78 |
| Price / Book: | 2.24 |
Profitability
| EPS (TTM): | 2.05310 |
|---|---|
| Net Income (TTM): | $162.5M |
| Gross Margin: | $40.3M |
| Return on Equity: | 95.25% |
| Return on Assets: | 60.21% |
CorMedix, Inc. Earnings Forecast
Key CorMedix, Inc. Financial Ratios
-
The Gross Profit Margin over the past 16 years for CRMD is 92.66%.
-
The Selling, General & Administrative Expenses for CRMD have been equal to 135.02% of Gross Profit Margin.
-
The Research & Development expenses have been 9.07% of Revenue.
-
The Net Earning history of CRMD is -41.24% of Total Revenues.
-
Per Share Earnings over the last 16 years have been positive in 10 years.
CorMedix, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Pharmaceuticals |
| Sector: | Health Care |
| Current Symbol: | CRMD |
| CUSIP: | 21900C |
| Website: | cormedix.com |
Debt
| Debt-to-Equity Ratio: | 0.01 |
|---|---|
| Current Ratio: | 1.94 |
| Quick Ratio: | 1.6 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 4.26 |
CRMD Technical Analysis vs Fundamental Analysis
Sell
44
CorMedix, Inc. (CRMD)
is a Sell
Is CorMedix, Inc. a Buy or a Sell?
-
CorMedix, Inc. stock is rated a SellThe current CorMedix, Inc. [CRMD] share price is $10.64. The Score for CRMD is 44, which is 12% below its historic median score of 50, and infers higher risk than normal.